Table of Contents
- Clinical trial overview
- Who the studies include
- Trial phases and main endpoints
- Cancer types studied
- Study designs and treatment combinations
- Trial status and enrollment
- Key patient-focused points
Clinical trial overview
The source data shows that Vibostolimab is being studied in cancer clinical trials, mostly as part of combination treatment plans.[1] These studies are looking at whether the treatment is safe and whether it helps control cancer better than the comparison treatment.[1]
The trials include different cancer settings, such as melanoma, lung cancer, bladder cancer, renal cell carcinoma, colorectal cancer, prostate cancer, and advanced solid tumors.[1] Some studies are completed, some are authorised, and some were withdrawn.[1]
Who the studies include
Each trial focuses on a specific patient group, so participation depends on the cancer type and other study details.[1] For example, some studies include people with PD-1 refractory melanoma, which means melanoma that did not respond well to earlier treatment with a PD-1 drug.[1]
Other studies include people with metastatic non-small cell lung cancer, extensive-stage small-cell lung cancer, high-risk non-muscle invasive bladder cancer, or renal cell carcinoma.[1] One withdrawn study also included pediatric and young adult participants with hematologic malignancies or solid tumors.[1]
Trial phases and main endpoints
The Vibostolimab studies in the data range from Phase 1 to Phase 4.[1] Phase 1 studies usually focus on safety and tolerability, while later phases often measure how well the treatment works in larger groups.[1]
Common endpoints include adverse events, objective response rate, progression-free survival, overall survival, recurrence-free survival, disease-free survival, and pathological complete response.[1] Some studies also measured dose-limiting toxicities and treatment stopping because of side effects.[1]
Several studies used blinded independent central review, which means expert reviewers checked the results without knowing which treatment each person received.[1] This helps make the results more reliable.[1]
Cancer types studied
Melanoma was studied in several trials, including studies in stage IIIB/IIIC/IIID melanoma, PD-1 refractory melanoma, and high-risk resected melanoma.[1] The melanoma trials looked at safety, objective response rate, pathological complete response, and recurrence-free survival.[1]
Non-small cell lung cancer (NSCLC) was another major area of study.[1] Trials included metastatic NSCLC, stage IV NSCLC, treatment-naïve NSCLC, and stage III lung cancer that could not be treated with surgery.[1] These studies looked mainly at overall survival, progression-free survival, and objective response rate.[1]
Other cancer types included small-cell lung cancer, bladder cancer, renal cell carcinoma, colorectal cancer, and metastatic castration-resistant prostate cancer.[1] In these studies, the main focus was usually how well the treatment worked and how safe it was.[1]
Study designs and treatment combinations
Most of the trials are interventional studies, which means the research team gives a treatment and then measures the results.[1] Vibostolimab is often tested with other cancer drugs, such as pembrolizumab, chemotherapy, or other investigational agents.[1]
Some studies compare a Vibostolimab-containing treatment with a control treatment such as pembrolizumab alone, placebo plus docetaxel, or other standard approaches listed in the trial records.[1] Several studies also included a safety lead-in phase, which is an early step used to check if a new combination can be tested safely before moving on.[1]
In the pediatric and young adult study, the source data also included drug level testing, such as area under the curve, maximum concentration, and trough concentration.[1] These are measures of how much of the study drug is in the blood over time.[1]
Trial status and enrollment
The data includes trials with a wide range of enrollment numbers, from 52 participants to 1,806 participants.[1] This shows that some studies were small early-phase trials, while others were large late-phase trials.[1]
Several studies are marked Completed, meaning the planned study work has finished.[1] Others are marked Authorised, meaning they are allowed to run, and a few are marked Withdrawn, meaning they were stopped before completion.[1]
Key patient-focused points
Vibostolimab is being studied in many different cancers, not just one disease.[1]
Most trials test Vibostolimab together with other treatments, so the results reflect combination therapy.[1]
The studies measure both safety and benefit, using outcomes like side effects, tumor response, and survival.[1]
Trial phases range from early safety testing to larger studies that compare survival outcomes.[1]
Eligibility depends on the exact cancer type and the rules written for each trial.[1]
